

Poster session 6 Saturday 7-9 AM

- P6-01-01** Patterns of disease progression in patients with local and metastatic breast cancer as evaluated by whole-body MRI
Kosmin M, Padhani A, Sokhi H, Thijssen T, Makris A.
- P6-01-02** Spatial heterogeneity of response on whole-body MRI to first line hormonal therapy predicts progression-free survival in metastatic breast cancer
Kosmin M, Makris A, Sokhi H, Thijssen T, Padhani A.
- P6-03-04** Central nervous system miliary metastasis in breast cancer patients
Bashour SI, Ibrahim NK, Schomer DF, Colen RR, Sawaya R, Suki D, Rao G, Murthy RK, Moulder SL, Abugabal Y, Hess KR, Fuller GN.
- P6-03-06** Assessing occult brain metastasis with CT scan or MRI in HER2-positive breast cancer patients at initial diagnosis
Delbaldo C, Sarrade T, Brieau B, Billefont B, Denis J, Cojean-Zelek I, Bornier C, Vincens E.
- P6-08-05** United States real-world drug utilization patterns and associated overall survival in Medicare patients with newly-diagnosed metastatic triple negative breast cancer using surveillance, epidemiology, and end results-Medicare data
Aly A, Shah R, Hill K, Waldeck AR, Botteman M.
- P6-08-10** Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort
Frank S, Tchokothe C, Carton M, Mouret-Fourme E, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'Hondt V, Debled M, Leheurteur M, Coudert B, Perrin C, Gonçalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Guesmia T, Bachelot T, Robain M, Cottu P.
- P6-08-11** Regional variation in de novo metastatic breast cancer survival improvement over time using an institutional registry to support SEER analysis: 1990-2010
Malmgren JA, Calip GS, Atwood MK, Kaplan HG.
- P6-09-09** Meta-analysis of ESR1 mutation prevalence in metastatic breast cancer
Mandó P, Rizzo MM, Perez de la Puente C, Costanzo MV, Nervo A, Nadal J, Colo F, Loza CM, Loza J, Fabiano V, Ponce C, Chacon R.
- P6-11-10** Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
Wallwiener M, Nabieva N, Haerberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg H-C, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V.
- P6-12-05** Metastatic breast cancer collateral damage project (MBCCD): Development and preliminary results of the survey of health, impact, needs, and experiences (SHINE)
Stanton A, Williamson T, Clague DeHart J, Jorge A, Eshraghi L, Cooper Ortner H, Love S.

- P6-12-07** Metastatic breast cancer collateral damage project: Associations of disease-specific concerns and experiences with psychological health, illness management, and health behaviors
Williamson T, Stanton A, Clague DeHart J, Jorge A, Eshraghi L, Cooper Ortner H, Love S.
- P6-12-13** Developing a non-hormonal treatment for vaginal dryness for breast cancer survivors: A pilot study of a therapeutic ultrasound device
MacLaughlan David S, Rockweiler H, Krone R, Middleton S, Blayney D.
- P6-14-02** Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program
Jacot W, Heudel P-E, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Courtinard C, Cottu P, Robain M, Mailliez A.
- P6-14-03** Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)
Aapro M, Ruiz Borrego M, Staroslawska E, Morales S, Ciniari S, De Freitas Junior R, Garcia Estevez L, Szombara E, Hervieu H, Groc M, Villanova G,
- P6-14-05** Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
Smith II J, Irwin A, Jensen L, Tedesco K, Misir S, Zhu W, Almonte A, He Y, Olivo M, O'Shaughnessy J.
- P6-14-06** Oral etoposide (VP-16) in heavily pre-treated metastatic breast cancer: A multicenter national observational study
Lerebours F, Carton M, Bacrie J, Pierga J-Y, Rouzier R, Saghatchian M, Dalenc F, Mailliez A, Levy C, Firmin N, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Goncalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Piot I, Perrocheau G, Caillot C, Perol D.